Tyrosine kinase Src is overexpressed and activated in various tumors, including breast cancer, and is supposed to promote cancer formation and development. Src 
| INTRODUCTION
Breast cancer is the most frequent malignancy, and is the second most common cause of cancer death among women according to the latest data. 1, 2 Targeted therapies have resulted in huge improvements in breast cancer treatment. Take trastuzumab as an example.
Addition of trastuzumab to chemotherapy has strikingly reduced the mortality rate of HER2-positive breast cancer and has emerged as a first-line treatment strategy for patients with HER2-positive breast cancer. 3 However, primary and/or acquired resistance occurs in the majority of patients receiving targeted therapy and eventually leads to the failure of treatment. 4 Regretfully, because of the complexity of breast cancer and the unique traits of targeted therapy, resistance to targeted therapy remains an obstacle in cancer treatment.
Src, an intracellular tyrosine kinase, plays a central role in cellular signaling pathways controlling proliferation and survival. [5] [6] [7] Src family kinases are confirmed in signal transduction downstream of multiple signaling networks, including ErbB receptor. 8 Increased Src activity has been observed in various cancers, such as breast, colon, liver, lung and pancreatic cancer. 7, [9] [10] [11] Moreover, a series of laboratory and clinical trials have implied that combination of Src inhibitor and anti-HER2 therapy showed efficacy in human breast cancer cells and primary tumors. 6, 12 Several studies have reported that the activation of Src might be an important factor in the process of trastuzumab resistance. 13 Furthermore, Rexer and colleagues confirmed that increased Src kinase activity contributes to lapatinib resistance and Fang and Jin equally contributed to this study.
proved that the combination of HER2 antagonists with Src inhibitors was a potent strategy to prevent or overcome HER2 inhibitor resistance in HER-positive breast cancer. 8 
| Colony formation assay
The SKBR-3 and SKBR-3/SI cells were seeded in 6-well plates at a density of 500-1000 cells per well for approximately 24 hours under standard conditions. After specific treatments, the cells then were exposed to saracatinib or human recombinant PAI-1. After 15 days of incubation, the colonies were fixed with methanol, stained with 0.5% crystal violet in absolute ethanol, and colonies with ≥50 cells were counted under a dissection microscope. These experiments were repeated at least 3 times. 
| Flow cytometry analysis

| Quantitative real-time PCR
Total RNA was extracted from cultured cells using Trizol Reagent of PAI-1, CCL5 and CCR5 was determined using the 2 ÀDDCt method.
| ELISA assay
Concentrations of PAI-1 and CCL5 in cell conditioned medium were determined using commercially available CCL5 (KEYGEN, KEGHC143, Nan Jing, China) and PAI-1 (KEYGEN, KEGHX025, Nan
Jing, China) ELISA kits. ELISA were performed according to the manufacturer's instructions.
| Western blot analysis
Total protein was extracted using RIPA buffer supplemented with protease inhibitors and quantified using a BCA Kit (Thermo Scien- siRNA targeting PAI-1 were transfected into cells using LipoFilter according its protocol (HanHeng, Shanghai, China). Protein extracts and drug treatments were started 48 hours after transfection.
| Immunohistochemistry
Following deparaffinization, sections were rehydrated and subjected to antigen retrieval using citrate buffer (BioGenex, USA). The slides were incubated with PAI-1 or CCL5 antibodies (1:200) at 4°C overnight. The following steps were performed as previously described.
The percentages of positive cells and staining intensities were scored as previously described. Figure 1A ,B). As for cell apoptosis, saracatinib markedly increased the early and later apoptosis rate of SKBR-3 but had no effect on SKBR-3/SI, suggesting the stable proliferation of resistant breast cancer cells ( Figure 1C ). Previous studies verified that breast cancer resistance protein (BCRP/ABCG2) was implicated in the development of anticancer resistance. 16 We also confirmed that BCRP was upregulated in SKBR-3/SI compared with SKBR-3 ( Figure 1D ). These data indicated that the saracatinib-resistant cell line was successfully established.
| PAI-1 was upregulated in saracatinib-resistant cell line
To explore whether certain factors conferred to resistance of saracatinib, we evaluated the mRNA expression profile between parental cell line SKBR-3 and resistant cell line SKBR-3/SI. On the basis of our laboratory's previous study results, which hint that PAI-1 accelerates malignancy in breast cancer and is a prominent factor during tumor development and progression, 17 we further found that mRNA expression of PAI-1 was increased in the resistant cell line. Interestingly, gene ontology analysis of genes with over 2-fold change between SKBR-3/SI and SKBR-3 revealed an enrichment of factors involved in positive regulation of monocyte chemotaxis, which also was reported to interact with PAI-1 to enhance disease progression of breast cancer in our early data ( Figure 2A ). 17 Hence, we chose PAI-1 for further research and confirmed that expression of PAI-1 in SKBR-3/SI was relatively higher in mRNA and protein levels than in SKBR-3 ( Figure 2B ,C). PAI-1 antagonist, PAI-039, respectively. We found that rPAI-1, which can mimic the function of PAI-1, decreased SKBR-3 cell sensitivity to saracatinib, while PAI-039, inhibiting PAI-1 activity, led to increased SKBR-3/SI cell sensitivity to saracatinib ( Figure 3A ). As shown in Figure 3B ,C, the treatment of rPAI-1 promoted cell proliferation in SKBR-3 while proliferation was inhibited by PAI-039 in SKBR-3/SI by using CCK8 assay and colony formation assay. We also observed that neither rPAI-1 nor PAI-039 had an effect on apoptosis ( Figure 3D ). Furthermore, transwell migration assay found that PAI-1could promote cell migration, while PAI-039 suppressed the cell migration in SKBR-3/SI ( Figure 3E ). In conclusion, these results showed that PAI-1 not only induces resistance to Src inhibitor in HER2-positive breast cancer cells, but also promotes the formation of tumor malignancy phenotype, such as proliferation and migration, which suggested that targeting PAI-1 might be a therapeutic option to restore sensitivity to saracatinib in resistant cells. 
| Effects of CCL5 on breast cancer cells
To further clarify the molecular mechanisms of saracatinib resistance, we treated SKBR-3 or SKBR-3/SI with recombinant human CCL5, which serves as exogenous CCL5, or a neutralizing CCL5 antibody (ab), respectively. It was observed that treatment with CCL5
decreased SKBR-3 cell sensitivity to saracatinib, whereas CCL5 ab induced increased SKBR-3/SI cell sensitivity to saracatinib (Figure 5A ). Colony formation assay also confirmed that CCL5 promoted cell proliferation in SKBR-3, while proliferation was inhibited by CCL5 ab in SKBR-3/SI ( Figure 5B ). Next, it was observed that cell F I G U R E 3 PAI-1 promoted Src inhibitor resistance, cell proliferation and migration in breast cells. A, Relative cell viability was determined in SKBR-3 and SKBR-3/SI cells following treatment with 10 ng/mL rPAI-1 and PAI-039 for 72 h by CCK8 assay. IC 50 values of SKBR-3 and SKBR-3/SI cells were presented in the mini-tables. B, OD value in SKBR-3 and SKBR-3/SI after treatment of 1, 10 or 100 lmol/L rPAI-1 and PAI-039, respectively, for 24, 48 and 72 h. C, Colony formation showed the proliferation of SKRB-3 and SKBR-3/SI after treatment of 10 ng/ mL rPAI-1 and PAI-039, respectively. D, Cell apoptosis of SKBR-3 and SKBR-3/SI after exposure to 10 ng/mL rPAI-1 or PAI-039 for 48 h was shown. E, Cell migration analysis in SKBR-3 and SKBR-3/SI cells treated with 10 ng/mL rPAI-1 and PAI-039 were performed. The error bars represent the mean of 3 separate determinations AE SD. *P < .05, **P < .01, ***P < .001
apoptosis of SKBR-3 was not influenced by CCL5 and CCL5 ab, as shown in Figure 5C . To assess the effect of CCL5 on cell migration, we performed a wound-healing assay and a transwell migration assay. As shown in Figure 5D ,E, it was observed that CCL5 treatment promoted SKBR-3 cell migration, whereas administration of CCL5 ab inhibited cell migration in SKBR-3/SI. Conclusively, CCL5 Taken together, our observations suggested that overexpressed PAI-1 might result in resistance to Src inhibitor in SKBR-3 by upregulating CCL5.
3.6 | PAI-1 and CCL5 expression was higher in SKBR-3/SI tumors compared to SKBR-3 tumors in vivo
To widen our scope of observations in vitro, we established a xenograft mouse model to evaluate the correlation between CCL5 and PAI-1 in vivo. As shown in Figure 6A , the mice treated with SKBR-3/SI had a bigger tumor size compared to the SKBR-3 group.
Moreover, tumor weights in the SKBR-3/SI group on day 42 after injection were significantly higher than in the SKBR-3 group (Figure 6B) . Figure 6C shows the HE staining of xenograft tissues and indicates that there is no difference in cell morphology between the SKBR-3 group and the SKBR-3/SI group. Furthermore, it was demonstrated that SKBR-3/SI tumors showed higher PAI-1 and CCL5
expression than SKBR-3 tumors, consistent with our in vitro data.
Besides, Ki67 stain of SKBR-3/SI tumors was also stronger than for SKBR-3 tumors, indicating the higher cell proliferation ( Figure 6D ). PAI-1 has been demonstrated to be involved in the development of tumors, contributing to tumor progression and angiogenesis.
| DISCUSSION
Expression of PAI-1 has also been identified as negatively associated with the prognosis of breast cancer patients. [20] [21] [22] 27 Based on these studies, we speculate that saracatinib resistance induced by CCL5 may be related to the abnormal activation of these 2 pathways, but further study is required to confirm this point. Besides, T.J. Curiel and his colleagues found that ovarian cancer stem-like cells, with the potential to develop drug resistance, displayed elevated expression of CCL5, which can recruit regulatory T cells. 32 Therefore, it is supposed that upregulated CCL5
in saracatinib-resistant SKBR-3/SI might interact with CCR5 on the surface of regulatory T cells, eventually leading to drug resistance.
In conclusion, our findings provide reliable evidence that the overexpression of PAI-1 contributes to Src inhibitor resistance in breast cancer via upregulating CCL5, and PAI-1 inhibitor could reverse saracatinib resistance in saracatinib-resistant cells. To make full use of Src inhibitor, it might be an option to combine agents targeting PAI-1 or CCL5 with Src inhibitor.
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